Teijin Limited

Lintec Corporation

Tsuneji Nagai

Yoshiki Suzuki

Hiroshi Ikura

Yoshiharu Machida

Gentaro Yamashita

Hideaki Okabe

Kunio Sekine

Yuji Nishimoto

Kozo Takayama

Naoki Nambu

A transdermal therapeutic formulation comprising d-limonene and at least one pharmaceutically active substance wherein the content of the d-limonene is in the range from 0.1 to 2 weight percent, based on the total amount of the formulation. The transdermal therapeutic formulation has an excellent percutaneous absorption, is safe and is capable of delivering desired pharmaceutically active substances to a desired location of treatment or to the entire body of a patient through the circulatory system and is thus effective for curing various diseases.

Transdermal therapeutic formulation containing a limonene

This invention is concerned with an oral sustained release pharmaceutical preparation which is prepared as a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs, or a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs together with a foaming agent, so that it may release the active drugs by such slow degrees in the stomach or the intestinal tract as to make it possible to provide an adequate supply of active drugs in enough concentration to display their therapeutic value for many hours.

Oral sustained release pharmaceutical preparation

The present invention relates to a method for treating an injured part on the oral mucosa, which comprises covering the injured part with a covering material consisting essentially of a cellulose lower alkyl ether and a polyacrylic acid or its pharmaceutically acceptable salt, and to said covering material. According to the present invention, without using a medicament, the injured part on an oral mucosa can be cured rather rapidly simply by covering the injured part.

Method of treating an injured part on the oral mucosa and the covering

What is provided by this invention is a powdery pharmaceutical composition for nasal administration comprising physiologically active polypeptide or its derivative such as calcitonin, insulin, etc. and a water-absorbing and water-insoluble base. The pharmaceutical composition allows polypeptide or its derivative to be efficiently absorbed through the nasal macous membrane when it is nasally administered.

Powdery pharmaceutical composition for nasal administration

A powdery pharmaceutical composition and a powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37.degree. C. for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug; and a method for treating or preventing a human nasal disease, which comprises administering a powdery preparation in unit dosage form to the nasal cavity of a human being requiring treatment or prevention of a nasal disease through his nostrils.

Powdery pharmaceutical composition and powdery preparation for

A method for administering a medicament which comprises adhering to the mucosa of the oral or nasal cavity a pharmaceutical preparation comprising

Growing community of inventors

Tokyo, Japan

Tsuneji Nagai